青光眼造成的失明通常是不可逆的，眼压升高被认为是青光眼的最重要危险因素。降眼压治疗可以延缓青光眼的发生和进展，是目前临床治疗青光眼的主要策略。视神经保护可能是青光眼治疗的新方向。从传统降眼压药物、新型降眼压药物、视神经保护药物3个方面对青光眼治疗药物进行综述和探讨。

Blindness from glaucoma is usually irreversible. Elevated intraocular pressure is considered the most important risk factor for glaucoma. Intraocular pressure lowering therapy can delay the occurrence and progression of glaucoma, and is currently the main strategy for clinical treatment of glaucoma. Optic-neuroprotection may be a new direction for glaucoma treatment. This article reviews and discusses glaucoma treatment drugs from three aspects, such as traditional ocular hypotensive drugs, new ocular hypotensive drugs, and optic nerve protection drugs.

R988.1

国家自然科学基金资助项目（81770923）